These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults. Buckley RF; Mormino EC; Rabin JS; Hohman TJ; Landau S; Hanseeuw BJ; Jacobs HIL; Papp KV; Amariglio RE; Properzi MJ; Schultz AP; Kirn D; Scott MR; Hedden T; Farrell M; Price J; Chhatwal J; Rentz DM; Villemagne VL; Johnson KA; Sperling RA JAMA Neurol; 2019 May; 76(5):542-551. PubMed ID: 30715078 [TBL] [Abstract][Full Text] [Related]
27. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Lantero Rodríguez J; Snellman A; Suárez-Calvet M; Blennow K; Zetterberg H; Schöll M; JAMA Neurol; 2021 Apr; 78(4):396-406. PubMed ID: 33427873 [TBL] [Abstract][Full Text] [Related]
28. APOE ε4 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly. Snellman A; Ekblad LL; Tuisku J; Koivumäki M; Ashton NJ; Lantero-Rodriguez J; Karikari TK; Helin S; Bucci M; Löyttyniemi E; Parkkola R; Karrasch M; Schöll M; Zetterberg H; Blennow K; Rinne JO Alzheimers Res Ther; 2023 Apr; 15(1):71. PubMed ID: 37016464 [TBL] [Abstract][Full Text] [Related]
29. Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer's Disease. Lantero-Rodriguez J; Salvadó G; Snellman A; Montoliu-Gaya L; Brum WS; Benedet AL; Mattsson-Carlgren N; Tideman P; Janelidze S; Palmqvist S; Stomrud E; Ashton NJ; Zetterberg H; Blennow K; Hansson O Mol Neurodegener; 2024 Feb; 19(1):19. PubMed ID: 38365825 [TBL] [Abstract][Full Text] [Related]
30. Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease. Quiroz YT; Sperling RA; Norton DJ; Baena A; Arboleda-Velasquez JF; Cosio D; Schultz A; Lapoint M; Guzman-Velez E; Miller JB; Kim LA; Chen K; Tariot PN; Lopera F; Reiman EM; Johnson KA JAMA Neurol; 2018 May; 75(5):548-556. PubMed ID: 29435558 [TBL] [Abstract][Full Text] [Related]
32. Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden. Buckley RF; Hanseeuw B; Schultz AP; Vannini P; Aghjayan SL; Properzi MJ; Jackson JD; Mormino EC; Rentz DM; Sperling RA; Johnson KA; Amariglio RE JAMA Neurol; 2017 Dec; 74(12):1455-1463. PubMed ID: 28973551 [TBL] [Abstract][Full Text] [Related]
33. Plasma Core Alzheimer's Disease Biomarkers Predict Amyloid Deposition Burden by Positron Emission Tomography in Chinese Individuals with Cognitive Decline. Ni M; Zhu ZH; Gao F; Dai LB; Lv XY; Wang Q; Zhu XX; Xie JK; Shen Y; Wang SC; Xie Q; ACS Chem Neurosci; 2023 Jan; 14(1):170-179. PubMed ID: 36547971 [TBL] [Abstract][Full Text] [Related]
34. Association between polygenic risk score of Alzheimer's disease and plasma phosphorylated tau in individuals from the Alzheimer's Disease Neuroimaging Initiative. Zettergren A; Lord J; Ashton NJ; Benedet AL; Karikari TK; Lantero Rodriguez J; ; Snellman A; Suárez-Calvet M; Proitsi P; Zetterberg H; Blennow K Alzheimers Res Ther; 2021 Jan; 13(1):17. PubMed ID: 33419453 [TBL] [Abstract][Full Text] [Related]
35. Pathologic and cognitive correlates of plasma biomarkers in neurodegenerative disease. Cousins KAQ; Phillips JS; Das SR; O'Brien K; Tropea TF; Chen-Plotkin A; Shaw LM; Nasrallah IM; Mechanic-Hamilton D; McMillan CT; Irwin DJ; Lee EB; Wolk DA Alzheimers Dement; 2024 Jun; 20(6):3889-3905. PubMed ID: 38644682 [TBL] [Abstract][Full Text] [Related]
36. Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients. Huang Y; Li Y; Xie F; Guo Q CNS Neurosci Ther; 2022 Dec; 28(12):2195-2205. PubMed ID: 36074638 [TBL] [Abstract][Full Text] [Related]
37. Modeling the temporal evolution of plasma p-tau in relation to amyloid beta and tau PET. Cogswell PM; Lundt ES; Therneau TM; Wiste HJ; Graff-Radford J; Algeciras-Schimnich A; Lowe VJ; Mielke MM; Schwarz CG; Senjem ML; Gunter JL; Knopman DS; Vemuri P; Petersen RC; Jack CR Alzheimers Dement; 2024 Feb; 20(2):1225-1238. PubMed ID: 37963289 [TBL] [Abstract][Full Text] [Related]
38. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease. Pereira JB; Janelidze S; Smith R; Mattsson-Carlgren N; Palmqvist S; Teunissen CE; Zetterberg H; Stomrud E; Ashton NJ; Blennow K; Hansson O Brain; 2021 Dec; 144(11):3505-3516. PubMed ID: 34259835 [TBL] [Abstract][Full Text] [Related]